ID   Mel202
AC   CVCL_C301
SY   MEL202; Mel-202; Mel 202; mel-202; EST128
DR   cancercelllines; CVCL_C301
DR   Cell_Model_Passport; SIDM01357
DR   Cosmic; 848329
DR   Cosmic; 899894
DR   Cosmic; 916143
DR   Cosmic; 1047643
DR   Cosmic; 1320372
DR   Cosmic; 1628395
DR   Cosmic; 2036706
DR   Cosmic; 2163830
DR   DepMap; ACH-001554
DR   ECACC; 13012457
DR   ESTDAB; ESTDAB-128
DR   GEO; GSM156005
DR   IARC_TP53; 26116
DR   Kerafast; EEE003
DR   Progenetix; CVCL_C301
DR   Wikidata; Q54905161
RX   PubMed=1748551;
RX   PubMed=17260012;
RX   PubMed=22236444;
RX   PubMed=22383533;
RX   PubMed=23851445;
RX   PubMed=24994677;
RX   PubMed=28018010;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 43 hours (PubMed=24994677).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu65Argfs*52 (c.194_201del) (p.Pro80fs, c.237_244del); Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Unspecified (PubMed=22236444; PubMed=23851445; PubMed=28018010; DepMap=ACH-001554).
CC   Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Arg210Lys (c.629G>A); Zygosity=Unspecified (PubMed=22236444; PubMed=23851445; PubMed=28018010; DepMap=ACH-001554).
CC   Sequence variation: Mutation; HGNC; 10768; SF3B1; Simple; p.Arg625Gly (c.1793C>T); ClinVar=VCV000376536; Zygosity=Unspecified (PubMed=24994677).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): DepMap=ACH-001554; ECACC=13012457; ESTDAB=ESTDAB-128; PubMed=22236444; PubMed=24994677
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11,13
ST   D16S539: 11,12
ST   D18S51: 12,15
ST   D21S11: 30.2,31.2
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   D8S1179: 13,16
ST   FGA: 23,24
ST   Penta D: 10,11
ST   Penta E: 7,13
ST   TH01: 6 (ECACC=13012457)
ST   TH01: 6,7 (DepMap=ACH-001554; ESTDAB=ESTDAB-128; PubMed=22236444; PubMed=24994677)
ST   TPOX: 8
ST   vWA: 18,19
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 28
//
RX   PubMed=1748551;
RA   Ksander B.R., Rubsamen P.E., Olsen K.R., Cousins S.W., Streilein J.W.;
RT   "Studies of tumor-infiltrating lymphocytes from a human choroidal
RT   melanoma.";
RL   Invest. Ophthalmol. Vis. Sci. 32:3198-3208(1991).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J.S., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=24994677; DOI=10.1016/j.molonc.2014.06.004;
RA   Amirouchene-Angelozzi N., Nemati F., Gentien D., Nicolas A.,
RA   Dumont A., Carita G., Camonis J., Desjardins L., Cassoux N.,
RA   Piperno-Neumann S., Mariani P., Sastre X., Decaudin D.,
RA   Roman-Roman S.;
RT   "Establishment of novel cell lines recapitulating the genetic
RT   landscape of uveal melanoma and preclinical validation of mTOR as a
RT   therapeutic target.";
RL   Mol. Oncol. 8:1508-1520(2014).
//
RX   PubMed=28018010;
RA   Jager M.J., Bermudez Magner J.A., Ksander B.R., Dubovy S.R.;
RT   "Uveal melanoma cell lines: where do they come from? (an American
RT   Ophthalmological Society thesis).";
RL   Trans. Am. Ophthalmol. Soc. 114:T5-T5(2016).
//